[1]
|
Weuve, J., Hebert, L.E., Scherr, P.A. and Evans, D.A. (2014) Deaths in the United States among Persons with Alzheimer’s Disease (2010–2050). Alzheimers & Dementia: The Journal of the Alzheimers Association, 10, e40-e46. https://doi.org/10.1016/j.jalz.2014.01.004
|
[2]
|
Kim, B. and Feldman, E.L. (2015) Insulin Resistance as a Key Link for the Increased Risk of Cognitive Impairment in the Metabolic Syndrome. Experimental & Molecular Medicine, 47, e149. https://doi.org/10.1038/emm.2015.3
|
[3]
|
Herrera, A.C., Prince, M., Knapp, M., Karagiannidou, M. and Guerchet, M. (2016) World Alzheimer Report 2016. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends.
|
[4]
|
Prince, M., Wimo, A., Guerchet, M., Ali, G.C., Wu, Y.T. and Prina, M. (2015) World Alzheimer Report 2015. The Global Impact of Dementia. An Analysis of Prevalence, Incidence, Cost and Trends.
|
[5]
|
Mckeith, I.G., Galasko, D., Kosaka, K., et al. (1996) Consensus Guidelines for Clinical and Pathological Diagnosis of Dementia with Lewy Bodies (DLB): Report of the CDLB International Workshop. Neurology, 47, 1113-1124. https://doi.org/10.1212/WNL.47.5.1113
|
[6]
|
Vickers, J.C., Dickson, T.C., Adlard, P.A., Saunders, H.L., King, C.E. and Mccormack, G. (2000) The Cause of Neuronal Degeneration in Alzheimer’s Disease. Progress in Neurobiology, 60, 139-165. https://doi.org/10.1016/S0301-0082(99)00023-4
|
[7]
|
Jack, C.R.Jr., Dickson, D.W., Parisi, J.E., et al. (2002) Antemortem MRI Findings Correlate with Hippocampal Neuropathology in Typical Aging and Dementia. Neurology, 58, 750-757. https://doi.org/10.1212/WNL.58.5.750
|
[8]
|
Bennett, D.A., Wilson, R.S., Schneider, J.A., et al. (2003) Apolipoprotein E epsilon4 allele, AD Pathology, and the Clinical Expression of Alzheimer’s Disease. Neurology, 60, 246-252. https://doi.org/10.1212/01.WNL.0000042478.08543.F7
|
[9]
|
Hoozemans, J.J., Veerhuis, R., Van Haastert, E.S., et al. (2005) The Unfolded Protein Response Is Activated in Alzheimer’s Disease. Acta Neuropathologica, 110, 165-172. https://doi.org/10.1007/s00401-005-1038-0
|
[10]
|
Hardy, J. (2002) Testing Times for the “Amyloid Cascade Hypothesis”. Neurobiology Aging, 23, 1073-1074. https://doi.org/10.1016/S0197-4580(02)00042-8
|
[11]
|
Mor, F. and Monsonego, A. (2006) Immunization Therapy in Alzheimer’s Disease. Expert Review of Neurotherapeutics, 6, 653-659. https://doi.org/10.1586/14737175.6.5.653
|
[12]
|
Mufson, E.J., Ikonomovic, M.D., Counts, S.E., et al. (2016) Molecular and Cellular Pathophysiology of Preclinical Alzheimer’s Disease. Behavioural Brain Research, 311, 54-69. https://doi.org/10.1016/j.bbr.2016.05.030
|
[13]
|
Qu, B., Boyer, P.J., Johnston, S.A., Hynan, L.S. and Rosenberg, R.N. (2006) Abeta42 Gene Vaccination Reduces Brain Amyloid Plaque Burden in Transgenic Mice. The Journal of the Neurological Sciences, 244, 151-158. https://doi.org/10.1016/j.jns.2006.02.006
|
[14]
|
Gilman, S., Koller, M., Black, R.S., et al. (2005) Clinical Effects of Abeta Immunization (AN1792) in Patients with AD in an Interrupted Trial. Neurology, 64, 1553-1562. https://doi.org/10.1212/01.WNL.0000159740.16984.3C
|
[15]
|
Fox, N.C., Black, R.S., Gilman, S., et al. (2005) Effects of Abeta Immunization (AN1792) on MRI Measures of Cerebral Volume in Alzheimer Disease. Neurology, 64, 1563-1572. https://doi.org/10.1212/01.WNL.0000159743.08996.99
|
[16]
|
Salloway, S., Sperling, R., Fox, N.C., et al. (2014) Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease. The New England Journal of Medicine, 370, 322-333. https://doi.org/10.1056/NEJMoa1304839
|
[17]
|
Doody, R.S., Thomas, R.G., Farlow, M., et al. (2014) Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer’s Disease. The New England Journal of Medicine, 370, 311-321. https://doi.org/10.1056/NEJMoa1312889
|
[18]
|
Cummings, J.L. (2004) Alzheimer’s Disease. The New England Journal of Medicine, 351, 56-67. https://doi.org/10.1056/NEJMra040223
|
[19]
|
Esposito, E., Rotilio, D., Di Matteo, V., Di Giulio, C., Cacchio, M. and Algeri, S. (2002) A Review of Specific Dietary Antioxidants and the Effects on Biochemical Mechanisms Related to Neurodegenerative Processes. Neurobiology of Aging, 23, 719-735. https://doi.org/10.1016/S0197-4580(02)00078-7
|
[20]
|
Lovell, M.A. and Markesbery, W.R. (2001) Ratio of 8-Hydroxyguanine in Intact DNA to Free 8-Hydroxyguanine Is Increased in Alzheimer Disease Ventricular Cerebrospinal Fluid. Archives of Neurology, 58, 392-396. https://doi.org/10.1001/archneur.58.3.392
|
[21]
|
Perry, G., Nunomura, A., Hirai, K., Takeda, A., Aliev, G. and Smith, M.A. (2000) Oxidative Damage in Alzheimer’s Disease: The Metabolic Dimension. International Journal of Developmental Neuroscience, 18, 417-421. https://doi.org/10.1016/S0736-5748(00)00006-X
|
[22]
|
Smith, M.A., Richey Harris, P.L., Sayre, L.M., Beckman, J.S. and Perry, G. (1997) Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease. The Journal of Neuroscience, 17, 2653-2657.
|
[23]
|
Mark, R.J., Pang, Z., Geddes, J.W., Uchida, K. and Mattson, M.P. (1997) Amyloid Beta-Peptide Impairs Glucose Transport in Hippocampal and Cortical Neurons: Involvement of Membrane Lipid Peroxidation. The Journal of Neuroscience, 17, 1046-1054.
|
[24]
|
Guglielmotto, M., Giliberto, L., Tamagno, E. and Tabaton, M. (2010) Oxidative Stress Mediates the Pathogenic Effect of Different Alzheimer’s Disease Risk Factors. Frontiers in Aging Neuroscience, 2, 3. https://doi.org/10.3389/neuro.24.003.2010
|
[25]
|
Kern, A. and Behl, C. (2009) The Unsolved Relationship of Brain Aging and Late-Onset Alzheimer Disease. Biochimica et Biophysica Acta, 1790, 1124-1132. https://doi.org/10.1016/j.bbagen.2009.07.016
|
[26]
|
Tamagno, E., Guglielmotto, M., Aragno, M., et al. (2008) Oxidative Stress Activates a Positive Feedback between the Gamma- and Beta-Secretase Cleavages of the Beta-Amyloid Precursor Protein. Journal of Neurochemistry, 104, 683-695.
|
[27]
|
Butterfield, D.A., Swomley, A.M. and Sultana, R. (2013) Amyloid Beta-Peptide (1-42)-Induced Oxidative Stress in Alzheimer Disease: Importance in Disease Pathogenesis and Progression. Antioxidants & Redox Signaling, 19, 823-835. https://doi.org/10.1089/ars.2012.5027
|
[28]
|
Tamagno, E., Guglielmotto, M., Monteleone, D. and Tabaton, M. (2012) Amyloid-Beta Production: Major Link between Oxidative Stress and BACE1. Neurotoxicity Research, 22, 208-219. https://doi.org/10.1007/s12640-011-9283-6
|
[29]
|
Tan, J.L., Li, Q.X., Ciccotosto, G.D., et al. (2013) Mild Oxidative Stress Induces Redistribution of BACE1 in Non-Apoptotic Conditions and Promotes the Amyloidogenic Processing of Alzheimer’s Disease Amyloid Precursor Protein. PLoS ONE, 8, e61246. https://doi.org/10.1371/journal.pone.0061246
|
[30]
|
Jiang, Y., Rigoglioso, A., Peterhoff, C.M., et al. (2016) Partial BACE1 Reduction in a Down Syndrome Mouse Model Blocks Alzheimer-Related Endosomal Anomalies and Cholinergic Neurodegeneration: Role of APP-CTF. Neurobiology of Aging, 39, 90-98. https://doi.org/10.1016/j.neurobiolaging.2015.11.013
|
[31]
|
Calsolaro, V. and Edison, P. (2016) Neuroinflammation in Alzheimer’s Disease: Current Evidence and Future Directions. Alzheimer’s & Dementia, 12, 719-732. https://doi.org/10.1016/j.jalz.2016.02.010
|
[32]
|
Kontush, A., Mann, U., Arlt, S., et al. (2001) Influence of Vitamin E and C Supplementation on Lipoprotein Oxidation in Patients with Alzheimer’s Disease. Free Radical Biology and Medicine, 31, 345-354. https://doi.org/10.1016/S0891-5849(01)00595-0
|
[33]
|
Salerno-Kennedy, R. and Cashman, K.D. (2005) Relationship between Dementia and Nutrition-Related Factors and Disorders: An Overview. International Journal for Vitamin and Nutrition Research, 75, 83-95. https://doi.org/10.1024/0300-9831.75.2.83
|
[34]
|
Whalley, L.J., Starr, J.M. and Deary, I.J. (2004) Diet and Dementia. Post Reproductive Health, 10, 113-117. https://doi.org/10.1258/1362180043654575
|
[35]
|
Holmes, C., Cunningham, C., Zotova, E., et al. (2009) Systemic Inflammation and Disease Progression in Alzheimer Disease. Neurology, 73, 768-774. https://doi.org/10.1212/WNL.0b013e3181b6bb95
|
[36]
|
Cunningham, C. (2013) Microglia and Neurodegeneration: The Role of Systemic Inflammation. Glia, 61, 71-90. https://doi.org/10.1002/glia.22350
|
[37]
|
McGeer, P.L. and McGeer, E.G. (2007) NSAIDs and Alzheimer Disease: Epidemiological, Animal Model and Clinical Studies. Neurobiology of Aging, 28, 639-647. https://doi.org/10.1016/j.neurobiolaging.2006.03.013
|
[38]
|
Sun, J., Zhang, S., Zhang, X., Zhang, X., Dong, H. and Qian, Y. (2015) IL-17A Is Implicated in Lipopolysaccharide-Induced Neuroinflammation and Cognitive Impairment in Aged Rats via Microglial Activation. Journal of Neuroinflammation, 12, 165. https://doi.org/10.1186/s12974-015-0394-5
|
[39]
|
Zhang, X.Y., Cao, J.B., Zhang, L.M., Li, Y.F. and Mi, W.D. (2015) Deferoxamine Attenuates Lipopolysaccharide-Induced Neuroinflammation and Memory Impairment in Mice. Journal of Neuroinflammation, 12, 20. https://doi.org/10.1186/s12974-015-0238-3
|
[40]
|
Craft, S. (2007) Insulin Resistance and Alzheimer’s Disease Pathogenesis: Potential Mechanisms and Implications for Treatment. Current Alzheimer Research, 4, 147-152. https://doi.org/10.2174/156720507780362137
|
[41]
|
Birch, A.M., Katsouri, L. and Sastre, M. (2014) Modulation of Inflammation in Transgenic Models of Alzheimer’s Disease. Journal of Neuroinflammation, 11, 25. https://doi.org/10.1186/1742-2094-11-25
|
[42]
|
Landreth, G.E. and Heneka, M.T. (2001) Anti-Inflammatory Actions of Peroxisome Proliferator-Activated Receptor Gamma Agonists in Alzheimer’s Disease. Neurobiology of Aging, 22, 937-944. https://doi.org/10.1016/S0197-4580(01)00296-2
|
[43]
|
Kitamura, Y., Shimohama, S., Koike, H., et al. (1999) Increased Expression of Cyclooxygenases and Peroxisome Proliferator-Activated Receptor-Gamma in Alzheimer’s Disease Brains. Biochemical and Biophysical Research Communications, 254, 582-586. https://doi.org/10.1006/bbrc.1998.9981
|
[44]
|
Ricote, M., Huang, J.T., Welch, J.S. and Glass, C.K. (1999) The Peroxisome Proliferator-Activated Receptor (PPARgamma) as a Regulator of Monocyte/Macrophage Function. Journal of Leukocyte Biology, 66, 733-739.
|
[45]
|
Murphy, G.J. and Holder, J.C. (2000) PPAR-Gamma Agonists: Therapeutic Role in Diabetes, Inflammation and Cancer. Trends in Pharmacological Sciences, 21, 469-474. https://doi.org/10.1016/S0165-6147(00)01559-5
|
[46]
|
Sastre, M. and Gentleman, S.M. (2010) NSAIDs: How They Work and Their Prospects as Therapeutics in Alzheimer’s Disease. Frontiers in Aging Neuroscience, 2, 20.
|
[47]
|
Mosconi, L., Pupi, A. and De Leon, M.J. (2008) Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer’s Disease. Annals of the New York Academy of Sciences, 1147, 180-195. https://doi.org/10.1196/annals.1427.007
|
[48]
|
Kim, B. and Feldman, E.L. (2015) Insulin Resistance as a Key Link for the Increased Risk of Cognitive Impairment in the Metabolic Syndrome. Experimental & Molecular Medicine, 47, e149. https://doi.org/10.1038/emm.2015.3
|
[49]
|
Craft, S. (2005) Insulin Resistance Syndrome and Alzheimer’s Disease: Age- and Obesity-Related Effects on Memory, Amyloid, and Inflammation. Neurobiology of Aging, 26, 65-69. https://doi.org/10.1016/j.neurobiolaging.2005.08.021
|
[50]
|
de la Monte, S.M. (2009) Insulin Resistance and Alzheimer’s Disease. BMB Reports, 42, 475-481. https://doi.org/10.5483/BMBRep.2009.42.8.475
|
[51]
|
Takashima, A. (2006) GSK-3 Is Essential in the Pathogenesis of Alzheimer’s Disease. Journal of Alzheimer’s Disease, 9, 309-317. https://doi.org/10.3233/JAD-2006-9S335
|
[52]
|
Cai, Z., Xiao, M., Chang, L. and Yan, L.J. (2015) Role of Insulin Resistance in Alzheimer’s Disease. Metabolic Brain Disease, 30, 839-851. https://doi.org/10.1007/s11011-014-9631-3
|
[53]
|
Son, S.M., Song, H., Byun, J., et al. (2012) Accumulation of Autophagosomes Contributes to Enhanced Amyloidogenic APP Processing under Insulin-Resistant Conditions. Autophagy, 8, 1842-1844. https://doi.org/10.4161/auto.21861
|
[54]
|
Yu, Y., Li, X., Blanchard, J., et al. (2015) Insulin Sensitizers Improve Learning and Attenuate Tau Hyperphosphorylation and Neuroinflammation in 3xTg-AD Mice. Journal of Neural Transmission (Vienna), 122, 593-606. https://doi.org/10.1007/s00702-014-1294-z
|
[55]
|
Escribano, L., Simon, A.M., Gimeno, E., et al. (2010) Rosiglitazone Rescues Memory Impairment in Alzheimer’s Transgenic Mice: Mechanisms Involving a Reduced Amyloid and Tau Pathology. Neuropsychopharmacology, 35, 1593-1604. https://doi.org/10.1038/npp.2010.32
|
[56]
|
Abbatecola, A.M., Lattanzio, F., Molinari, A.M., et al. (2010) Rosiglitazone and Cognitive Stability in Older Individuals with Type 2 Diabetes and Mild Cognitive Impairment. Diabetes Care, 33, 1706-1711. https://doi.org/10.2337/dc09-2030
|
[57]
|
Fei, L., Yong-Jun, H., Zhang-Min, M., et al. (2015) Rosiglitazone Attenuates Memory Impairment in Aged Rat with Diabetes by Inhibiting NF-Kappa B Signal Pathway Activation. Experimental and Clinical Endocrinology & Diabetes, 123, 536-542. https://doi.org/10.1055/s-0035-1559607
|
[58]
|
Watson, G.S., Cholerton, B.A., Reger, M.A., et al. (2005) Preserved Cognition in Patients with Early Alzheimer Disease and Amnestic Mild Cognitive Impairment during Treatment with Rosiglitazone: A Preliminary Study. The American Journal of Geriatric Psychiatry, 13, 950-958.
|
[59]
|
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H. and Iwamoto, T. (2011) Efficacy of PPAR-Gamma Agonist Pioglitazone in Mild Alzheimer Disease. Neurobiology of Aging, 32, 1626-1633. https://doi.org/10.1016/j.neurobiolaging.2009.10.009
|
[60]
|
Geldmacher, D.S., Fritsch, T., McClendon, M.J. and Landreth, G. (2011) A Randomized Pilot Clinical Trial of the Safety of Pioglitazone in Treatment of Patients with Alzheimer Disease. Archives of Neurology, 68, 45-50. https://doi.org/10.1001/archneurol.2010.229
|
[61]
|
Feingold, K.R., Grunfeld, C., Heuer, J.G., et al. (2012) FGF21 Is Increased by Inflammatory Stimuli and Protects Leptin-Deficient ob/ob Mice from the Toxicity of Sepsis. Endocrinology, 153, 2689-2700. https://doi.org/10.1210/en.2011-1496
|
[62]
|
Fisher, F.M. and Maratos-Flier, E. (2016) Understanding the Physiology of FGF21. Annual Review of Physiology, 78, 223-241. https://doi.org/10.1146/annurev-physiol-021115-105339
|
[63]
|
Sa-Nguanmoo, P., Chattipakorn, N. and Chattipakorn, S.C. (2016) Potential Roles of Fibroblast Growth Factor 21 in the Brain. Metabolic Brain Disease, 31, 239-248. https://doi.org/10.1007/s11011-015-9789-3
|
[64]
|
Kharitonenkov, A. (2009) FGFs and Metabolism. Current Opinion in Pharmacology, 9, 805-810. https://doi.org/10.1016/j.coph.2009.07.001
|
[65]
|
Ogawa, Y., Kurosu, H., Yamamoto, M., et al. (2007) βKlotho Is Required for Metabolic Activity of Fibroblast Growth Factor 21. Proceedings of the National Academy of Sciences of the United States of America, 104, 7432-7437. https://doi.org/10.1073/pnas.0701600104
|
[66]
|
Adams, A.C., Cheng, C.C., Coskun, T. and Kharitonenkov, A. (2012) FGF21 Requires Betaklotho to Act in Vivo. PLoS ONE, 7, e49977. https://doi.org/10.1371/journal.pone.0049977
|
[67]
|
Ge, H., Baribault, H., Vonderfecht, S., et al. (2012) Characterization of a FGF19 Variant with Altered Receptor Specificity Revealed a Central Role for FGFR1c in the Regulation of Glucose Metabolism. PLoS ONE, 7, e33603. https://doi.org/10.1371/journal.pone.0033603
|
[68]
|
Yang, C., Jin, C., Li, X., Wang, F., McKeehan, W.L. and Luo, Y. (2012) Differential Specificity of Endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in Complex with KLB. PLoS ONE, 7, e33870. https://doi.org/10.1371/journal.pone.0033870
|
[69]
|
Tomiyama, K., Maeda, R., Urakawa, I., et al. (2010) Relevant Use of Klotho in FGF19 Subfamily Signaling System in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 107, 1666-1671. https://doi.org/10.1073/pnas.0913986107
|
[70]
|
Makela, J., Tselykh, T.V., Maiorana, F., et al. (2014) Fibroblast Growth Factor-21 Enhances Mitochondrial Functions and Increases the Activity of PGC-1Alpha in Human Dopaminergic Neurons via Sirtuin-1. SpringerPlus, 3, 2. https://doi.org/10.1186/2193-1801-3-2
|
[71]
|
Leng, Y., Wang, Z., Tsai, L.K., et al. (2015) FGF-21, a Novel Metabolic Regulator, Has a Robust Neuroprotective Role and Is Markedly Elevated in Neurons by Mood Stabilizers. Molecular Psychiatry, 20, 215-223. https://doi.org/10.1038/mp.2013.192
|
[72]
|
Tan, B.K., Hallschmid, M., Adya, R., Kern, W., Lehnert, H. and Randeva, H.S. (2011) Fibroblast Growth Factor 21 (FGF21) in Human Cerebrospinal Fluid: Relationship with Plasma FGF21 and Body Adiposity. Diabetes, 60, 2758-2762. https://doi.org/10.2337/db11-0672
|
[73]
|
Hsuchou, H., Pan, W. and Kastin, A.J. (2007) The Fasting Polypeptide FGF21 Can Enter Brain from Blood. Peptides, 28, 2382-2386. https://doi.org/10.1016/j.peptides.2007.10.007
|
[74]
|
Liang, Q., Zhong, L., Zhang, J., et al. (2014) FGF21 Maintains Glucose Homeostasis by Mediating the Cross Talk between Liver and Brain during Prolonged Fasting. Diabetes, 63, 4064-4075. https://doi.org/10.2337/db14-0541
|
[75]
|
Bookout, A.L., de Groot, M.H., Owen, B.M., et al. (2013) FGF21 Regulates Metabolism and Circadian Behavior by Acting on the Nervous System. Nature Medicine, 19, 1147-1152. https://doi.org/10.1038/nm.3249
|
[76]
|
Fon Tacer, K., Bookout, A.L., Ding, X., et al. (2010) Research Resource: Comprehensive Expression Atlas of the Fibroblast Growth Factor System in Adult Mouse. Molecular Endocrinology, 24, 2050-2064. https://doi.org/10.1210/me.2010-0142
|
[77]
|
Chau, M.D., Gao, J., Yang, Q., Wu, Z. and Gromada, J. (2010) Fibroblast Growth Factor 21 Regulates Energy Metabolism by Activating the AMPK-SIRT1-PGC-1Alpha Pathway. Proceedings of the National Academy of Sciences of the United States of America, 107, 12553-12558. https://doi.org/10.1073/pnas.1006962107
|
[78]
|
Ye, D., Wang, Y., Li, H., et al. (2014) Fibroblast Growth Factor 21 Protects against Acetaminophen-Induced Hepatotoxicity by Potentiating Peroxisome Proliferator-Activated Receptor Coactivator Protein-1Alpha-Mediated Antioxidant Capacity in Mice. Hepatology, 60, 977-989. https://doi.org/10.1002/hep.27060
|
[79]
|
Fisher, F.M., Kleiner, S., Douris, N., et al. (2012) FGF21 Regulates PGC-1Alpha and Browning of White Adipose Tissues in Adaptive Thermogenesis. Genes & Development, 26, 271-281. https://doi.org/10.1101/gad.177857.111
|
[80]
|
Potthoff, M.J., Inagaki, T., Satapati, S., et al. (2009) FGF21 Induces PGC-1Alpha and Regulates Carbohydrate and Fatty Acid Metabolism during the Adaptive Starvation Response. Proceedings of the National Academy of Sciences of the United States of America, 106, 10853-10858. https://doi.org/10.1073/pnas.0904187106
|
[81]
|
Katsouri, L., Blondrath, K. and Sastre, M. (2012) Peroxisome Proliferator-Activated Receptor-Gamma Cofactors in Neurodegeneration. IUBMB Life, 64, 958-964. https://doi.org/10.1002/iub.1097
|
[82]
|
Austin, S. and St-Pierre, J. (2012) PGC1Alpha and Mitochondrial Metabolism—Emerging Concepts and Relevance in Ageing and Neurodegenerative Disorders. Journal of Cell Science, 125, 4963-4971. https://doi.org/10.1242/jcs.113662
|
[83]
|
Qin, W., Haroutunian, V., Katsel, P., et al. (2009) PGC-1Alpha Expression Decreases in the Alzheimer Disease Brain as a Function of Dementia. Archives of Neurology, 66, 352-361. https://doi.org/10.1001/archneurol.2008.588
|
[84]
|
Katsouri, L., Parr, C., Bogdanovic, N., Willem, M. and Sastre, M. (2011) PPARγ Co-Activator-1α (PGC-1α) Reduces Amyloid-β Generation through a PPARγ-Dependent Mechanism. Journal of Alzheimer’s Disease, 25, 151-162.
|
[85]
|
Katsouri, L., Lim, Y.M., Blondrath, K., et al. (2016) PPARγ-Coactivator-1α Gene Transfer Reduces Neuronal Loss and Amyloid-β generation by Reducing β-Secretase in an Alzheimer’s Disease Model. Proceedings of the National Academy of Sciences of the United States of America, 113, 12292-12297. https://doi.org/10.1073/pnas.1606171113
|
[86]
|
Planavila, A., Redondo, I., Hondares, E., et al. (2013) Fibroblast Growth Factor 21 Protects against Cardiac Hypertrophy in Mice. Nature Communications, 4, Article No. 2019. https://doi.org/10.1038/ncomms3019
|
[87]
|
Planavila, A., Redondo-Angulo, I., Ribas, F., et al. (2015) Fibroblast Growth Factor 21 Protects the Heart from Oxidative Stress. Cardiovascular Research, 106, 19-31. https://doi.org/10.1093/cvr/cvu263
|
[88]
|
Yu, Y., Bai, F., Wang, W., et al. (2015) Fibroblast Growth Factor 21 Protects Mouse Brain against D-Galactose Induced Aging via Suppression of Oxidative Stress Response and Advanced Glycation end Products Formation. Pharmacology, Biochemistry and Behavior, 133, 122-131. https://doi.org/10.1016/j.pbb.2015.03.020
|
[89]
|
Breitner, J.C. (1996) The Role of Anti-Inflammatory Drugs in the Prevention and Treatment of Alzheimer’s Disease. Annual Review of Medicine, 47, 401-411. https://doi.org/10.1146/annurev.med.47.1.401
|
[90]
|
Akiyama, H., Barger, S., Barnum, S., et al. (2000) Inflammation and Alzheimer’s Disease. Neurobiology of Aging, 21, 383-421. https://doi.org/10.1016/S0197-4580(00)00124-X
|
[91]
|
Heneka, M.T. and O’Banion, M.K. (2007) Inflammatory Processes in Alzheimer’s Disease. Journal of Neuroimmunology, 184, 69-91. https://doi.org/10.1016/j.jneuroim.2006.11.017
|
[92]
|
Kim, H.W., Lee, J.E., Cha, J.J., et al. (2013) Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice. Endocrinology, 154, 3366-3376. https://doi.org/10.1210/en.2012-2276
|
[93]
|
Yu, Y., He, J., Li, S., et al. (2016) Fibroblast Growth Factor 21 (FGF21) Inhibits Macrophage-Mediated Inflammation by Activating Nrf2 and Suppressing the NF-κB Signaling Pathway. International Immunopharmacology, 38, 144-152. https://doi.org/10.1016/j.intimp.2016.05.026
|
[94]
|
Xu, J., Lloyd, D.J., Hale, C., et al. (2009) Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice. Diabetes, 58, 250-259. https://doi.org/10.2337/db08-0392
|
[95]
|
So, W.Y., Cheng, Q., Xu, A., Lam, K.S. and Leung, P.S. (2015) Loss of Fibroblast Growth Factor 21 Action Induces Insulin Resistance, Pancreatic Islet Hyperplasia and Dysfunction in Mice. Cell Death & Disease, 6, e1707. https://doi.org/10.1038/cddis.2015.80
|
[96]
|
Sarruf, D.A., Thaler, J.P., Morton, G.J., et al. (2010) Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats. Diabetes, 59, 1817-1824. https://doi.org/10.2337/db09-1878
|
[97]
|
Qing, Y., Yang, J. and Wan, C. (2015) Increased Serum Fibroblast Growth Factor 21 Levels in Patients with Schizophrenia. Australian and New Zealand Journal of Psychiatry, 49, 849-850. https://doi.org/10.1177/0004867415575380
|
[98]
|
Inagaki, T., Dutchak, P., Zhao, G., et al. (2007) Endocrine Regulation of the Fasting Response by PPARα-Mediated Induction of Fibroblast Growth Factor 21. Cell Metabolism, 5, 415-425. https://doi.org/10.1016/j.cmet.2007.05.003
|